...we get killed on the EU problem - The European Medicines Agency declined the waiver of the "PIP"...Pediatric Investigation Plan...And who ever heard that ACAD had an issue with a Pediatric waiver anyway? This is a problem because whom ever is in charge of the EU filing does not have enough experience. Again, lack of a EU Partner. They don't even know how long it will take to get this waiver issue completed. But other good things, ADP Phase 2 Proof of Concept trial - enrollment completed Mid'16, Data Q4 '16. ADA Phase 2 starts Q2 '16. Cash $457Mill...
So you are thinking today is Reversal day....well the present candlestick pattern is definitely showing signs of Bearish slowing, but remember a Reversal is only noted AFTER it occurs. Not sure if you timing is good or not, But in the long run you will be ok.
Presently cleaning out a 30x10 storage unit, keep some stuff and donate or toss the other junk. Same with this guys article-It's not a bad article, but his valuation is just terrible. I would totally disregard his numbers that seem to be way off. But other parts are interesting regarding Partnership.
Type Value Conf.
resist. 39.25 2
resist. 36.14 6
resist. 34.39 9
resist. 31.63 13
resist. 28.15 3
supp 25.69 2
supp 24.52 2
supp 23.63 2
supp 21.24 5
supp 19.23 2
supp 17.32 4
That major resistance at $34 has dispersed and now the strong R is $31.63. Price now $27.53, Small candle, Cross your fingers we see a little green.
1 month of Nuplazid is far cheaper to either hospitalize the patient or give current drugs with side effects that will either result in the patient stopping the medication or worsening their Parkinson's . There are systems in place that can help patients pay for the meds....Regarding reimbursement; let me start out by saying we are confident NUPLAZID will be reimbursed by the vast majority of payers. All of our market research indicates payers view NUPLAZID as having unique benefits for patients and based on the size of the PDP patient population in the United States and the number of PDP patients and their individual plans, adding NUPLAZID to the formularies should have little impact on their budgets.
Now just as a reminder to everyone, our market research indicates our payer mix will almost be two-thirds Medicare Part D plans, almost a third commercial and we will have the remainder covered under Medicaid. NUPLAZID is an oral product and covered as a pharmacy benefit. So it does not need a J Code and does not require a physician to take on any financial risk. So, I’ll switch gears a little bit and talk about our plans to help patients with PDP who are prescribed NUPLAZID and how we can help them get the product.
We have a strong commitment to help ensure that every patient with hallucinations and delusions associated with PDP and who is likely to benefit from NUPLAZID can get access to the product. While we mentioned our patient assistance program, NUPLAZIDconnect, in our press release, I wanted to expand on some of the key points.
At the center of NUPLAZIDconnect is our Physician and Patient Support Services Center for navigating the increasingly complex insurance environment covering benefit certification, prior authorizations and, when appropriate, appeals. These services will assist physicians and patients with obtaining access for prescriptions that are consistent with the FDA approved indication. ( I couldn't put the whole thing here....)
MNKD's drug was not one of a kind, or first in class and they didn't have the world wide rights ----In fact
AFREZZA's oral inhaled insulin was the 2nd inhaled insulin drug tried - the first oral inhaled insulin FAILED and was taken off the market. So recall the definition of insanity....trying the same thing and expecting different results. Also they had a partner that gave up and returned full control back to MNKD, they didn't want anything to do with it. Just too much competition. So you can see MNKD has very little in common with ACAD. So...get lost....I mean, just saying.
Will give Davis the benefit of the doubt for now - hoping he has some answers tomorrow and he makes a come back ...
Well its not that Davis is a bad speaker, he just not saying what we want to hear.
if Davis says we launch sales on June 1....then I am happy as a clam. If he says the EU NDA will be submitted on June 30....I am exhilarated. If he says...The price of Nuplazid will be $12,750 per year, ie $1062 per month supply well I get happy.....if he says we are now going to initiate a Partner search for the ROW I will die and go to heaven....But he didn't....He didn't come close on most of those issues. And there is the little factoid of the IBB taking it in the Bung. But lets see how he does tomorrow. He needs to check off at least 2 of the above items tomorrow. My guess is 1) Pricing and either 2) Launch date or EU NDA date.
Come on Davis give us something !
I don't think they have to shop it, ...if you build it they will come...is more my thinking and they built it...so its just a matter of time before MRK, JNJ or PFE come knocking at the door. Biotech will always drive you nuts. Hoping to see a smaller sell (small red candle ) tomorrow then a reversal?
Yes, you can buy or sell at the wrong time. The key is if you understand and believe in the science then you know you will do well in the long term. This is one of those Biotech gopher holes you don't see. We have a Billion dollar drug
APPROVED...this is not the time to sell,
ACADIA's management will host a conference call and webcast on Thursday, May 5, 2016, at 5:00 p.m. Eastern Time to discuss ACADIA’s financial results and operations.